T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice
Open Access
- 3 June 2026
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Abstract
Objective: The biomarker potential of CD4+ T-cell subsets [naive, regulatory (Treg), inflammation-related cells (IRC)] in patients with rheumatoid arthritis (RA) has been described. This article investigates the dynamic changes in these biomarkers across the RA disease continuum from at-risk to drug-induced remission. Methods: T-cell subset biomarker data were acquired using flow cytometry. Multiple group comparisons were performed using ANOVA test (with Bonferroni correction). Results: In individuals at risk of RA, longitudinal analysis showed that IRC frequencies increased just prior to onset of clinical synovitis, while naive T-cell frequencies reduced in those progressing to clinical synovitis, but increased in non-progressors. The use of naive/IRC data improved the accuracy of RA classification, especially in ACPA-negative patients. A distinct T-cell biomarker signature was observed in late-onset RA (>60 years old vs <59). In untreated RA, the predictive value of naive T-cell frequencies for methotrexate response was confirmed. For patients on methotrexate, naive T cells increased only between 6 and 12 months and only when in remission. IRC and Treg showed no consistent change. In patients treated with TNF inhibitors, naive T-cell frequency increased independently of response, whilst sustained IRC reductions and Treg increases were seen in remission. Once in stable clinical remission, only naive frequencies increased with the length of remission on conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), whilst only Treg increased over time in TNF inhibitor-induced remission. Conclusion: These studies validated that T-cell subset measurements are independent from other currently used biomarkers, highlighting differences in the impact of drug modes of action on the three T-cell subsets. There is still an unmet need for biomarkers to predict response to TNF inhibition in early RA.Keywords
Funding Information
- Alzheimer's Research Trust
This publication has 56 references indexed in Scilit:
- Predicting Flare in Patients With Rheumatoid Arthritis in Biologic Induced Remission, on Tapering, and on Stable TherapyACR Open Rheumatology, 2024
- Gut microbiota in pre-clinical rheumatoid arthritis: From pathogenesis to preventing progressionJournal of Autoimmunity, 2023
- Best practices for addressing missing data through multiple imputationInfant and Child Development, 2023
- Control of naive and effector CD4 T cell receptor repertoires by rheumatoid-arthritis-risk HLA allelesJournal of Autoimmunity, 2022
- Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studiesEBioMedicine, 2022
- Auto-antibodies to post-translationally modified proteins in osteoarthritisOsteoarthritis and Cartilage, 2021
- Individuals at risk of rheumatoid arthritis – The evolving storyBest Practice & Research Clinical Rheumatology, 2017
- Changes in peripheral blood immune cell composition in osteoarthritisOsteoarthritis and Cartilage, 2015
- The prevalence of autoantibodies against cartilage intermediate layer protein, YKL-39, osteopontin, and cyclic citrullinated peptide in patients with early-stage knee osteoarthritis: evidence of a variety of autoimmune processesRheumatology International, 2004
- Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donorsArthritis & Rheumatism, 2004